Discovery of Novel KRAS-PDEδ Inhibitors by Fragment-Based Drug Design,Journal of Medicinal Chemistry

当前位置： X-MOL 学术 › J. Med. Chem. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Discovery of Novel KRAS-PDEδ Inhibitors by Fragment-Based Drug Design
Journal of Medicinal Chemistry ( IF 6.8 ) Pub Date : 2018-03-06 00:00:00 , DOI: 10.1021/acs.jmedchem.8b00057
Long Chen ₁ , Chunlin Zhuang ₁ , Junjie Lu ₁ , Yan Jiang ₁ , Chunquan Sheng ₁

Affiliation

Targeting KRAS-PDEδ protein–protein interactions with small molecules represents a promising opportunity for developing novel antitumor agents. However, current KRAS-PDEδ inhibitors are limited by poor cellular antitumor potency and the druggability of the target remains to be validated by new inhibitors. To tackle these challenges, herein, novel, highly potent KRAS-PDEδ inhibitors were identified by fragment-based drug design, providing promising lead compounds or chemical probes for investigating the biological functions and druggability of KRAS-PDEδ interaction.

中文翻译：

基于片段的药物设计发现新型KRAS-PDEδ抑制剂

靶向KRAS-PDEδ蛋白与小分子的相互作用代表了开发新型抗肿瘤药物的有希望的机会。然而，目前的KRAS-PDEδ抑制剂受到细胞抗肿瘤能力差的限制，并且靶标的可药用性仍有待新抑制剂的验证。为了解决这些挑战，本文通过基于片段的药物设计鉴定了新型，高效的KRAS-PDEδ抑制剂，为研究KRAS-PDEδ相互作用的生物学功能和可药用性提供了有前途的先导化合物或化学探针。

更新日期：2018-03-06

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南11